BR112021005645A2 - oligonucleotídeo, composição farmacêutica, método de prevenção e uso - Google Patents

oligonucleotídeo, composição farmacêutica, método de prevenção e uso Download PDF

Info

Publication number
BR112021005645A2
BR112021005645A2 BR112021005645-9A BR112021005645A BR112021005645A2 BR 112021005645 A2 BR112021005645 A2 BR 112021005645A2 BR 112021005645 A BR112021005645 A BR 112021005645A BR 112021005645 A2 BR112021005645 A2 BR 112021005645A2
Authority
BR
Brazil
Prior art keywords
oligonucleotide
patient
ulcerative colitis
weeks
use according
Prior art date
Application number
BR112021005645-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Arezou Zargar
Pernilla Sandwall
Charlotte Admyre
Thomas Knittel
Peter Zerhouni
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of BR112021005645A2 publication Critical patent/BR112021005645A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112021005645-9A 2018-11-14 2019-11-14 oligonucleotídeo, composição farmacêutica, método de prevenção e uso BR112021005645A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1818579.3 2018-11-14
GBGB1818579.3A GB201818579D0 (en) 2018-11-14 2018-11-14 New therapy
PCT/EP2019/081377 WO2020099585A1 (en) 2018-11-14 2019-11-14 New therapy

Publications (1)

Publication Number Publication Date
BR112021005645A2 true BR112021005645A2 (pt) 2021-06-29

Family

ID=64739449

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021005645-9A BR112021005645A2 (pt) 2018-11-14 2019-11-14 oligonucleotídeo, composição farmacêutica, método de prevenção e uso

Country Status (10)

Country Link
US (1) US20220218736A1 (https=)
EP (1) EP3880303A1 (https=)
JP (1) JP2022507493A (https=)
KR (1) KR20210092719A (https=)
CN (1) CN113226461A (https=)
AU (1) AU2019378077A1 (https=)
BR (1) BR112021005645A2 (https=)
CA (1) CA3118899A1 (https=)
GB (1) GB201818579D0 (https=)
WO (1) WO2020099585A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4147688A1 (en) 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP2596806A1 (en) * 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201707500D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2

Also Published As

Publication number Publication date
GB201818579D0 (en) 2018-12-26
KR20210092719A (ko) 2021-07-26
JP2022507493A (ja) 2022-01-18
WO2020099585A1 (en) 2020-05-22
US20220218736A1 (en) 2022-07-14
AU2019378077A1 (en) 2021-04-22
EP3880303A1 (en) 2021-09-22
CN113226461A (zh) 2021-08-06
CA3118899A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
US20240043847A1 (en) New therapy
AU2023237033A1 (en) Cobitolimod for use in the treatment of inflammatory bowel disease
EP3947685B1 (en) Oligonucleotide-based therapy for ulcerative colitis
BR112021005645A2 (pt) oligonucleotídeo, composição farmacêutica, método de prevenção e uso
WO2018206713A1 (en) Cobitolimod for use in the treatment of inflammatory bowel disease
HK40059650B (en) Oligonucleotide-based therapy for ulcerative colitis
HK40059650A (en) Oligonucleotide-based therapy for ulcerative colitis
KR20230112664A (ko) 자가-투여를 위한 코비톨리모드 투여량
KR20230128510A (ko) 관장기 제형

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.